Oral Hsp90 inhibitor SNX-5422 attenuates SARS-CoV-2 replication and dampens inflammation in airway cells
© 2021 The Author(s)..
Currently available SARS-CoV-2 therapeutics are targeted toward moderately to severely ill patients and require intravenous infusions, with limited options for exposed or infected patients with no or mild symptoms. Although vaccines have demonstrated protective efficacy, vaccine hesitancy and logistical distribution challenges will delay their ability to end the pandemic. Hence, there is a need for rapidly translatable, easy-to-administer-therapeutics that can prevent SARS-CoV-2 disease progression, when administered in the early stages of infection. We demonstrate that an orally bioavailable Hsp90 inhibitor, SNX-5422, currently in clinical trials as an anti-cancer therapeutic, inhibits SARS-CoV-2 replication in vitro at a high selectivity index. SNX-5422 treatment of human primary airway epithelial cells dampened expression of inflammatory pathways previously associated with poor SARS-CoV-2 disease outcomes. In addition, SNX-5422 interrupted expression of host factors demonstrated to be crucial for SARS-CoV-2 replication. Development of SNX-5422 as SARS-CoV-2-early-therapy will dampen disease severity, resulting in better clinical outcomes and reduced hospitalizations.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
iScience - 24(2021), 12 vom: 17. Dez., Seite 103412 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Goswami, Ria [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 08.11.2023 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.isci.2021.103412 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM33324219X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM33324219X | ||
| 003 | DE-627 | ||
| 005 | 20231225221244.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.isci.2021.103412 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1110.xml |
| 035 | |a (DE-627)NLM33324219X | ||
| 035 | |a (NLM)34786537 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Goswami, Ria |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Oral Hsp90 inhibitor SNX-5422 attenuates SARS-CoV-2 replication and dampens inflammation in airway cells |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 08.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2021 The Author(s). | ||
| 520 | |a Currently available SARS-CoV-2 therapeutics are targeted toward moderately to severely ill patients and require intravenous infusions, with limited options for exposed or infected patients with no or mild symptoms. Although vaccines have demonstrated protective efficacy, vaccine hesitancy and logistical distribution challenges will delay their ability to end the pandemic. Hence, there is a need for rapidly translatable, easy-to-administer-therapeutics that can prevent SARS-CoV-2 disease progression, when administered in the early stages of infection. We demonstrate that an orally bioavailable Hsp90 inhibitor, SNX-5422, currently in clinical trials as an anti-cancer therapeutic, inhibits SARS-CoV-2 replication in vitro at a high selectivity index. SNX-5422 treatment of human primary airway epithelial cells dampened expression of inflammatory pathways previously associated with poor SARS-CoV-2 disease outcomes. In addition, SNX-5422 interrupted expression of host factors demonstrated to be crucial for SARS-CoV-2 replication. Development of SNX-5422 as SARS-CoV-2-early-therapy will dampen disease severity, resulting in better clinical outcomes and reduced hospitalizations | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Therapeutics | |
| 650 | 4 | |a Virology | |
| 700 | 1 | |a Russell, Veronica S |e verfasserin |4 aut | |
| 700 | 1 | |a Tu, Joshua J |e verfasserin |4 aut | |
| 700 | 1 | |a Thomas, Charlene |e verfasserin |4 aut | |
| 700 | 1 | |a Hughes, Philip |e verfasserin |4 aut | |
| 700 | 1 | |a Kelly, Francine |e verfasserin |4 aut | |
| 700 | 1 | |a Langel, Stephanie N |e verfasserin |4 aut | |
| 700 | 1 | |a Steppe, Justin |e verfasserin |4 aut | |
| 700 | 1 | |a Palmer, Scott M |e verfasserin |4 aut | |
| 700 | 1 | |a Haystead, Timothy |e verfasserin |4 aut | |
| 700 | 1 | |a Blasi, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Permar, Sallie R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t iScience |d 2018 |g 24(2021), 12 vom: 17. Dez., Seite 103412 |w (DE-627)NLM285332627 |x 2589-0042 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2021 |g number:12 |g day:17 |g month:12 |g pages:103412 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.isci.2021.103412 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2021 |e 12 |b 17 |c 12 |h 103412 | ||